

An aerial night view of the Toronto skyline, featuring the CN Tower and various skyscrapers illuminated against a dark blue sky. The city lights create a vibrant, glowing effect.

2026
BLOOM BURTON & CO.
HEALTHCARE INVESTOR
CONFERENCE

BBHIC
2026

METRO TORONTO CONVENTION CENTRE
APRIL 21-22, 2026

**BLOOM BURTON & CO. EXISTS
TO ACCELERATE RETURNS IN
THE HEALTHCARE SECTOR
FOR BOTH COMPANIES AND
INVESTORS.**

**THERE IS NO GREATER
ILLUSTRATION OF THE
POWER OF OUR PLATFORM
THAN THIS CONFERENCE,
WHICH HAS GROWN INTO
CANADA'S FLAGSHIP
HEALTHCARE INVESTMENT
AND NETWORKING EVENT.**

WELCOME!

Welcome to the 2026 Bloom Burton & Co. Healthcare Investor Conference!

Bloom Burton & Co. is solely dedicated to accelerating the path to monetization for healthcare companies and investors; we do so through our specialized services which include raising equity and debt capital, M&A advisory, equity research, sales and trading, strategic advisory, and creating and incubating new companies. We work with organizations of every stage of development and in every area of healthcare, including biotechnology, pharmaceuticals, medical technology, healthcare services, digital health, research and manufacturing tools, pharma services, as well as animal and consumer health.

There is no greater expression of the breadth of our work than the annual Bloom Burton & Co. Healthcare Investor Conference, which is Canada's flagship event for global investors to meet Canada's leading companies, and the ecosystem which supports them.

This year we are hosting the tenth edition of the Bloom Burton Award Gala. We are honoured, once again, to bring everyone together and celebrate Canadian excellence in healthcare. We look forward to seeing everyone dressed to impress in black-tie, cheering on their colleagues and collaborators at the 2026 Bloom Burton Award Gala on September 24, 2026 at The Ritz-Carlton, Toronto. This year's three finalists will be announced this week, during the lunch hour of the conference.

We are always impressed with the advancement of the healthcare industry – even during times of uncertainty – and we remain committed to serving as a force for strategic growth in our industry.

We are also proud of our brilliant and dedicated team, who work tirelessly to produce exceptional work and support positive outcomes for all of our clients. Our entire team is here for you this week as you make new connections and plan for the success of the healthcare sector in Canada and beyond.

We wish you a wonderful conference.

A stylized, handwritten signature in white ink, consisting of several overlapping loops and a long horizontal stroke extending to the right.A handwritten signature in white ink that reads "Jolyn Burton". The signature is fluid and cursive, with the first name being more prominent.

The Bloom Burton & Co. Team

TABLE OF CONTENTS

ABOUT	3
AGENDA	4
KEYNOTE SPEAKER	6
INVESTING IN COMMERCIAL-STAGE HEALTHCARE COMPANIES PANEL	9
INVESTING IN R&D-STAGE HEALTHCARE COMPANIES PANEL	12
PRESENTING COMPANIES	18
ABOUT BLOOM BURTON & CO.	52
BLOOM BURTON & CO. SERVICES	54
SPONSORS	56
CONFERENCE INFORMATION	58



NETWORK: BLOOM BURTON & CO.
PASSWORD: BBHIC2026

2026 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE



The 2026 Bloom Burton & Co. Healthcare Investor Conference takes place on April 21-22, 2026 at the Metro Toronto Convention Centre.

We have invited 66 of Canada's premier and most promising publicly-traded and private companies in the healthcare industry to attend and present to our audience of Canadian, U.S. and international investors.

At the conference, investors and company management have the opportunity to meet one-on-one. We also provide a stage for industry leaders to discuss the latest news and share insights on the ups and downs of the market and the state of the global healthcare industry.

AGENDA

TUESDAY, APRIL 21

8:30 AM	Breakfast and Opening Remarks	Plenary Room 106/107	REGISTRATION OPENS AT 8:00 AM
9:30 AM	Toronto Stock Exchange Opening		

	ROOM 104 C/D	ROOM 104 B	ROOM 104 A
9:30 AM	NASDAQ:ZYME Zymeworks Biotechnology	TSX-V:PCR PharmaCorp Rx Healthcare Services	Private CorVista Medical Technology
10:00 AM	Private Acuitas Therapeutics Biotechnology	Private KYE Pharmaceuticals Pharmaceutical	TSX-V:PINK Perimeter Medical Imaging Medical Technology
10:30 AM	NASDAQ:JBIO Jade Biosciences Biotechnology	Private ANB Canada Pharma Services	Private Yellowbird Diagnostics Medical Technology
11:00 AM	NASDAQ:EPRX, TSX:EPRX Eupraxia Pharmaceuticals Biotechnology	Private Celystra Pharma Pharmaceutical	Private Exact Imaging Medical Technology
11:30 AM	NASDAQ:MSLE, TSX:MSCL Satellos Bioscience Biotechnology	Private Pharmascience Pharmaceutical	Private Intellijoint Surgical Medical Technology

12:00 PM	Lunch	Plenary Room 106/107
12:30 PM	Keynote Speaker E. Eric Tokat, Co-President of Investment Banking at Centerview Partners	

	ROOM 104 C/D	ROOM 104 B	ROOM 104 A
1:30 PM	NASDAQ:ABCL AbCellera Biologics Biotechnology	TSX:MDP Medexus Pharma Pharmaceutical	Private Flosonics Medical Medical Technology
2:00 PM	NASDAQ:HELP, CBOE:HELP Helus Pharma Biotechnology	TSX:GUD Knight Therapeutics Pharmaceutical	Private Fluid Biomed Medical Technology
2:30 PM	NASDAQ:PMN ProMIS Neurosciences Biotechnology	TSX-V:RX BioSyent Pharmaceutical	Private Epitopea Biotechnology
3:00 PM	TSX:MDNA Medicenna Therapeutics Biotechnology	TSX:HLS HLS Therapeutics Pharmaceutical	Private AtomVie Global Radiopharma Pharma Services
3:30 PM	NASDAQ:EDSA Edesa Biotech Biotechnology	TSX-V:WOLF Grey Wolf Animal Health Pharmaceutical	Private Nualtis Pharma Services
4:00 PM	Private Congruence Therapeutics Biotechnology	TSX-V:LSL Groupe LSL Pharma Pharma Services	Private Virica Biotech Pharma Services

5:00 PM	Bloom Burton & Co. Cocktail Reception Steam Whistle Brewing, 255 Bremner Blvd.		
---------	---	--	--

WEDNESDAY, APRIL 22

1X1 MEETING SESSIONS - ROOM 105
9:30 AM-12:00 PM & 1:30 PM-5:00 PM
APRIL 21 & APRIL 22

8:20 AM	Breakfast and Opening Remarks	Plenary Room 106/107
8:30 AM	Investing in Commercial-Stage Healthcare Companies Panel Adam Kaye (RA Capital Management), Karim Maasarani (Eckuity Capital), Shaunak Parikh (Invidia Capital Management), Jon Plexico (Stonepine Capital Management)	

	ROOM 104 C/D	ROOM 104 B	ROOM 104 A
9:30 AM	TSX:WELL WELL Health Technologies Healthcare Services	TSX-V:CNVI Conavi Medical Medical Technology	Private Reverb Therapeutics Biotechnology
10:00 AM	Private Custom Health Healthcare Services	NASDAQ:PROF, TSX:PRN Profound Medical Medical Technology	Private DCx Biotherapeutics Biotechnology
10:30 AM	Private WELLSTAR Digital Health	TSX:EDT Spectral Medical Medical Technology	Private Aspect Biosystems Biotechnology
11:00 AM	TSX:CRRX CareRx Healthcare Services	Private Thornhill Medical Medical Technology	NASDAQ:NGEN NervGen Pharma Biotechnology
11:30 AM	TSX:VHI VitalHub Digital Health	Private MolecuLight Medical Technology	NASDAQ:XENE Xenon Pharmaceuticals Biotechnology

12:00 PM	Lunch	Plenary Room 106/107
12:30 PM	Investing in R&D-Stage Healthcare Companies Panel Roberto Bellini (BSQUARED Capital), Kasia Konopacki (Marshall Wace Asset Management), Isai Peimer (Balyasny Asset Management), Brad Sitko (XOMA Royalty)	

	ROOM 104 C/D	ROOM 104 B	ROOM 104 A
1:30 PM	TSX:RIC Richards Group Pharma Services	Private Canary Medical Medical Technology	TSX-V:TTI Thiogenesis Therapeutics Biotechnology
2:00 PM	TSX:AIDX HEALWELL AI Digital Health	TSX:MBX Microbix Biosystems Medical Technology	Private Specific Biologics Biotechnology
2:30 PM	TSX-V:NPTH NeuPath Health Healthcare Services	Private Nicoya Lifesciences Medical Technology	Private ProteinQure Biotechnology
3:00 PM	Private Northwyn Wellness Group Healthcare Services	TSX-V:CHER Cheelcare Medical Technology	Private Feldan Therapeutics Biotechnology
3:30 PM	CSE:BETR BetterLife Pharma Biotechnology	Private Sonic Incytes Medical Technology	Private Altis Labs Pharma Services
4:00 PM	Private Oligon Therapeutics Biotechnology	Private Synaptive Medical Medical Technology	Private Innospera Pharma Biotechnology

KEYNOTE SPEAKER



E. ERIC TOKAT

Co-President of Investment Banking at Centerview Partners

APRIL 21, 2026
12:30 PM - 1:30 PM
PLENARY ROOM 106/107

ABOUT E. ERIC TOKAT

E. Eric Tokat is Co-President of Investment Banking at Centerview Partners, a leading independent investment bank with offices in New York, San Francisco, Menlo Park, London and Paris.

Mr. Tokat has been critical in helping to build Centerview into a preeminent advisory firm and positioning it for continued success. As Co-President of Investment Banking, he works with fellow members of Centerview's senior management in overseeing and implementing the firm's strategy and continuing to develop its industry-leading client franchises.

Mr. Tokat is a founder of Centerview's Healthcare practice and has played an instrumental role in establishing the practice as the market leader in strategic advisory. Mr. Tokat has advised on more than 100 transactions over his career exceeding \$500 billion in total deal value, including many of the most important, industry-defining life sciences transactions of the past decade. He is a frequent speaker on Healthcare industry trends and has been quoted in leading publications including The Wall Street Journal, The Financial Times, Bloomberg News and STAT News.

Mr. Tokat has been involved in numerous educational and charitable causes throughout his career and currently serves on a number of not-for-profit boards, including as: a trustee at the Brookings Institution, a member of the Board of Advisors at the IRC (International Rescue Committee), a member of the Board of Advisors at Columbia University Irving Medical Center and Vagelos College of Physicians and Surgeons, as well as a member of the Board of Advisors of Columbia University School of International and Public Affairs. He is also a member of the Council on Foreign Relations.

Mr. Tokat received his BA from Bogazici University and Master of International Affairs from Columbia University.



BB
20
25
H1Q

E!



BB
20
25
H1Q

INVESTING IN COMMERCIAL-STAGE HEALTHCARE COMPANIES PANEL

ADAM KAYE
RA CAPITAL MANAGEMENT

KARIM MAASARANI
ECKUITY CAPITAL

SHAUNAK PARIKH
INVIDIA CAPITAL MANAGEMENT

JON PLEXICO
STONEPINE CAPITAL MANAGEMENT

Wednesday April 22, 2026
8:30 AM - 9:30 AM
Plenary Room 106/107

INVESTING IN COMMERCIAL-STAGE HEALTHCARE COMPANIES PANEL



ADAM KAYE

Senior Managing Director and Partner,
Structured Capital

RA Capital Management

Adam Kaye is a Senior Managing Director and Partner, Structured Capital at RA Capital Management. His primary responsibility is to build out credit and structured capital solutions across the RA Capital platform with a focus on commercial stage healthcare and life sciences companies. Adam has spent the last 20 years working across credit and equity investing and was previously a Managing Director at two large credit focused platforms, Sixth Street Partners and Hayfin Capital Management. Prior to Hayfin, he was at New Health Capital Partners, a life sciences and health care special situations fund. Adam's investing career began at New Leaf Venture Partners, a private venture fund focused on biotech, medical devices and diagnostics companies across venture and public equity opportunities. Prior to New Leaf he was a healthcare investment banker at ThinkEquity Partners, and BMO Capital Markets. He holds a MS in Biology from New York University and BBA in Finance and Consulting from Emory University's Goizueta Business School.



KARIM MAASARANI

General Partner

Eckuity Capital

Karim Maasarani is a General Partner at Eckuity Capital, where he focuses on identifying and scaling disruptive innovations across medical technology, digital health, and biotechnology. He brings more than 15 years of experience spanning life sciences investing, corporate strategy, and healthcare operations, combining technical expertise with a disciplined investment approach that drives strategic and commercial value across the portfolio. Before joining Eckuity, Karim was a Vice President at Amzak Health, where he led growth-stage investments in medtech and biotech, with a focus on AI-enabled platforms and next-generation therapeutic technologies. He also served as Board Member and Interim CEO of Si Paradigm, a specialty diagnostics company where he led operational transformation and profitability initiatives. Karim was previously at Merck in its Strategy & Business Development group, Dentsply Sirona and Becton Dickinson. Karim holds Bachelor's and Master's degrees in Biomedical Engineering from the New Jersey Institute of Technology and an MBA with Honors from Columbia Business School.

INVESTING IN COMMERCIAL-STAGE HEALTHCARE COMPANIES PANEL



SHAUNAK PARIKH

Partner

Invidia Capital Management

Shaunak Parikh is a Partner at Invidia with nearly 20 years of experience at the intersection of healthcare and finance. His focus has been on identifying, evaluating, and executing investments across pharma and pharma services, medical devices, diagnostics, and technology-enabled services. He brings extensive board experience, working closely with management teams to drive growth and value creation. Prior to Invidia, Mr. Parikh was an investor at EW Healthcare Partners in New York and at a San Francisco-based private equity firm focused on healthcare. He began his career in the investment banking group at Citi, advising on M&A transactions in the medical device and pharmaceutical sectors. Mr. Parikh earned his MBA from The Wharton School at the University of Pennsylvania and graduated Phi Beta Kappa with Honors from UCLA with dual degrees in Microbiology, Immunology & Molecular Genetics and Economics.



JON PLEXICO

Managing Member

Stonepine Capital Management

Jon has approximately 32 years of life science industry operational and advisory experience, including fourteen years as Principal and Founder of Stonepine. Previously, Mr. Plexico was Managing Director at Merriman Curhan Ford & Co., where he ran healthcare corporate finance focusing on private investments in public equity (PIPEs), secondary offerings, and mergers and acquisitions. Prior to that, Mr. Plexico was co-founding partner of Venture Ready Partners, a life science advisor providing capital raising services to private biotechnology companies. Previously, Mr. Plexico was employee #5 at Chemdex, an electronic life-science commerce company that grew to 500 employees and completed an initial public offering during his tenure. He began his career at Quidel Corporation, where he became National Sales Manager for the Autoimmune Division. He has served on the Boards of Directors of Zila, Inc., Immunetech, Inc., and Viveve Medical, Inc. Mr. Plexico is a graduate of Colgate University.

INVESTING IN R&D-STAGE HEALTHCARE COMPANIES PANEL

ROBERTO BELLINI
BSQUARED CAPITAL

KASIA KONOPACKI
MARSHALL WACE ASSET MANAGEMENT

ISAI PEIMER
BALYASNY ASSET MANAGEMENT

BRAD SITKO
XOMA ROYALTY

Wednesday April 22, 2026
12:30 PM - 1:30 PM
Plenary Room 106/107

INVESTING IN R&D-STAGE HEALTHCARE COMPANIES PANEL



ROBERTO BELLINI

Managing Partner

BSQUARED Capital

Roberto Bellini is a Managing Partner at BSQUARED Capital, a family office biotech fund, that he co-founded in 2023. He also serves as Director on the Board of Inhibikase Therapeutics [NASDAQ:IKT] and Congruence Therapeutics. He served as President and CEO of BELLUS Health between January 2010 and July 2023. Under his leadership, BELLUS Health developed a P2X3 antagonist, camlipixant, for chronic cough from preclinical to Phase 3 and was acquired by GSK plc for US\$2.0B in 2023. Mr. Bellini holds a Bachelor of Science in Biochemistry from McGill University.



KASIA KONOPACKI

Healthcare Investor

Marshall Wace Asset Management

Kasia is a healthcare investor at Marshall Wace, where she focuses on late-stage private and public investment opportunities. Her work centers on evaluating clinical and regulatory catalysts alongside commercial viability to uncover underappreciated opportunities in the market. Prior to Marshall Wace, Kasia was an oncology investor at Avoro Capital, and before that she completed her PhD in the lab of Sasha Rudensky at Memorial Sloan Kettering. Outside of work, she enjoys skiing and art.

INVESTING IN R&D-STAGE HEALTHCARE COMPANIES PANEL



ISAI PEIMER

Portfolio Manager

Balyasny Asset Management

Isai Peimer is a seasoned biotech investor and Portfolio Manager at Balyasny Asset Management, specializing in private and public therapeutic investments. Since 2008, he has focused on partnering with management teams to advance the development of breakthrough therapies. Previously, Isai was a biotech investor at a multi-strategy hedge fund and served as Managing Director at a corporate venture fund. He has held board positions at multiple biotech companies, providing strategic guidance through critical development and M&A milestones. Isai's career began in the pharmaceutical industry and included roles in investment banking, equity research, and management consulting. He holds a B.S. in Chemistry, summa cum laude, from Emory University and an M.B.A. from the Tuck School of Business at Dartmouth.



BRAD SITKO

Chief Investment Officer

XOMA Royalty

Brad Sitko has been XOMA Royalty's Chief Investment Officer since January 2023. Brad has been involved with 70+ diverse transactions including royalty monetization, structured finance, buy and sell-side M&A, spinouts, divestitures, in- and out-licensing, PIPEs, private placements, and follow-ons with over \$9B of M&A, licensing volume and capital raised in healthcare, biotech and digital health sectors. Transaction roles include investor, operating company executive, financial advisor and strategy consultant. Prior to XOMA Royalty, Mr. Sitko served as Managing Director, Strategic Finance, at RTW Investments, LP, a global, full life-cycle investment firm in the biopharmaceutical and medical technology sectors where he led the royalty monetization, structured finance and alternatives efforts of the firm. Brad was also previously a member of the Board of RTW Investments ICAV, Chief Financial Officer of Ji Xing Pharmaceuticals Limited, Vice President, Finance, Operations and Corporate Development of DNAnexus, Inc., and Director at MTS Health Partners. Mr. Sitko received a B.A. in History and Sociology of Science from the University of Pennsylvania and an M.B.A. from Columbia Business School.



2026
BLOOM BURTON & CO.
HEALTHCARE INVESTOR
CONFERENCE

COCKTAIL
RECEPTION


BBHIC

2026

**APRIL 21, 2026
5:00 PM**

**LOCOMOTIVE HALL @ STEAM WHISTLE BREWING
255 BREMNER BLVD.**

PRESENTING COMPANIES



This year's Bloom Burton & Co. Healthcare Investor Conference hosts 66 of Canada's premier and most promising publicly-traded and private companies in the healthcare industry in the following six areas:

BIOTECHNOLOGY

PHARMACEUTICAL

MEDICAL TECHNOLOGY

PHARMA SERVICES

HEALTHCARE SERVICES

DIGITAL HEALTH

AbCellera Biologics

Tuesday April 21 | 1:30 PM

Room 104 C/D



AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women's health, immunology, oncology, and more.

Acuitas Therapeutics

Tuesday April 21 | 10:00 AM

Room 104 C/D



Acuitas Therapeutics Inc., the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with biotech companies, academic researchers, and global health organizations. Acuitas' clinically validated LNP has enabled two products as well as 33 clinical trials over the last three years. Today, Acuitas is advancing next-generation LNP to support therapies including targeted LNP for extrahepatic and in vivo CAR-T cell therapies, epigenetic medicines, multivalent infectious disease vaccines, as well as oncology vaccines, including personalized cancer vaccines. Acuitas, at BBHIC, welcomes meetings with companies exploring the potential of LNP technology. If you are interested in learning more about our LNP platform and discussing how it may complement your technology, we would be pleased to connect.

Altis Labs

Wednesday April 22 | 3:30 PM

Room 104 A

Δ L T I S L A B S

Altis Labs is the computational imaging company accelerating clinical trials with AI. Altis has trained proprietary AI models on the industry's largest multimodal training database spanning over 200 million longitudinal images linked to clinical, molecular, and outcomes data. Top 20 biopharma use Altis' AI models to more confidently analyze data from phase 1-4 clinical trials so that they can bring the most effective novel treatments to patients sooner.

ANB Canada

Tuesday April 21 | 10:30 AM

Room 104 B



For over 30 years, ANB Canada has been a trusted full-service partner and Canadian ally in the Over-The-Counter (OTC), Sports Nutrition, HABA, and RX industries. We provide comprehensive support in warehousing, distribution, sales, Health Canada compliance, marketing, advertising, and industry trade show representation, helping our partners succeed in the Canadian market.

Aspect Biosystems

Wednesday April 22 | 10:30 AM
Room 104 A



Aspect Biosystems is a biotechnology company pioneering the development of a novel category of cellular medicines designed to replace or restore biological function and deliver curative therapies for some of the most elusive diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypimmune cell engineering, and advanced biomaterials. Aspect is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine disorders.

AtomVie Global Radiopharma

Tuesday April 21 | 3:00 PM
Room 104 A



AtomVie Global Radiopharma Inc. (AtomVie) is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality and logistics services combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies, phases I to III, to the commercial markets. Currently, AtomVie serves international clients conducting clinical studies in over 28 countries worldwide. AtomVie is in the process of constructing and commissioning a new state-of-art purpose-built, scalable 72,300 sq ft cGMP facility, set for operational readiness in 2026.

BetterLife Pharma

Wednesday April 22 | 3:30 PM
Room 104 C/D



BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

BioSyent

Tuesday April 21 | 2:30 PM
Room 104 B



Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty healthcare company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.

Canary Medical

Wednesday April 22 | 1:30 PM
Room 104 B



Canary Medical is a medical technology company pioneering active implantable platforms and AI-driven analytics to build a future where connected devices continuously inform treatment and lower the overall cost of healthcare. Its patented canturio[®]te technology powers the world's first FDA-approved smart knee that autonomously collects and transmits objective mobility and joint performance data from inside the body. Canary has built one of the largest real-world datasets in total joint arthroplasty, supporting more informed clinical decisions and measurable improvements in patient recovery. The company is leveraging its core sensing, power, and data architecture to expand intelligent implants across additional therapeutic categories.

CareRx

Wednesday April 22 | 11:00 AM
Room 104 C/D



At CareRx, we are shaping the future of senior care through pharmacy services that make a real difference. As Canada's trusted leader in specialty pharmacy services for long-term care, retirement and congregate living communities, we are committed to enhancing the health of Canadians with unique and complex medication needs. Our goal is to improve clinical outcomes and provide personalized care every step of the way.

Celystra Pharma

Tuesday April 21 | 11:00 AM

Room 104 B



Celystra Pharma is a Quebec-based biopharmaceutical company specializing in the introduction of innovative treatments to Canada. Founded by three pharmaceutical industry veterans, the company identifies and acquires innovative therapies developed internationally and brings them to underserved patient populations in Canada. Based in Montreal and active within Quebec's life sciences ecosystem, Celystra works with global partners to help bring new treatments to patients who need them.

Cheelcare

Wednesday April 22 | 3:00 PM

Room 104 B



Cheelcare is a Canadian mobility technology company that designs and manufactures innovative solutions that empower greater independence for people with disabilities. The Company's product portfolio spans power-assist devices and complex-rehab technology, including its Companion™ power assist line and the Curio™ robotic complex-rehab power wheelchair. Cheelcare combines engineering excellence with human-centered design to deliver durable, high-performance mobility products that support everyday function, confidence, and quality of life for users and caregivers. With a focus on clinically relevant innovation and real-world usability, Cheelcare aims to advance mobility outcomes across both community and complex-rehab settings.

Conavi Medical

Wednesday April 22 | 9:30 AM
Room 104 B



Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, enabling simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid™ System has regulatory clearance in the U.S., Canada, China, and Japan.

Congruence Therapeutics

Tuesday April 21 | 4:00 PM
Room 104 C/D



Congruence is a clinical-stage, computationally driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Their proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. Congruence has leveraged its proprietary discovery engine to launch a pipeline of wholly owned drugs directed to high-value, genetically validated, difficult-to-drug targets spanning a variety of indications including genetic obesity, GBA Parkinson's Disease, and α 1-Antitrypsin Deficiency. Congruence is further deploying its discovery platform to support its multi-target research collaborations with large pharmaceutical companies focused on the discovery of small molecule correctors and allosteric modulators for the treatment of diseases in oncology, metabolic disease, neurology and immunology.

CorVista

Tuesday April 21 | 9:30 AM
Room 104 A



CorVista Health is dedicated to transforming cardiovascular care through innovative diagnostics that shorten the path from symptoms to diagnosis. By enabling earlier detection of complex cardiovascular conditions, CorVista aims to empower clinicians with actionable insights and improve patient outcomes across diverse care settings.

Custom Health

Wednesday April 22 | 10:00 AM
Room 104 C/D



Custom Health helps people who take medication have the best possible health outcome. We connect patients with their circle of care, help them to take meds as prescribed with easy-to-use digital health tools, then go beyond adherence to make sure those meds are doing what they should. Our integrated healthcare delivery model includes personalized medication management, always-on clinical oversight, remote patient monitoring, and home-based care. Some say we're obsessed with the journey of a pill, and to that we say, absolutely! And proud of it. We make it easy for people to take their meds as prescribed, we make sure they're working as intended, and we take action when they're not. We care for people the way we care for our families, and treat people the way we want to be treated.

DCx Biotherapeutics Corporation

Wednesday April 22 | 10:00 AM
Room 104 A



We strive to address the root drivers of cancer by uncovering key cellular interdependencies that result from genetic lesions. We can realize the full potential of antibody drug conjugates by targeting lesion-defined and synergistic targets to improve selectivity, potency, and tolerability with the ultimate aim to maximize clinical responses and durability.

Edesa Biotech

Tuesday April 21 | 3:30 PM
Room 104 C/D



Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% danilumer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis, a common occupational skin condition. The company's most advanced Respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a U.S. government-funded platform study as a treatment for Acute Respiratory Distress Syndrome, a life-threatening form of respiratory failure. The EB05 program has been the recipient of two funding awards from the Government of Canada to support the further development of this asset. Edesa is also pursuing additional uses for paridiprubart.

Epitopea

Tuesday April 21 | 2:30 PM

Room 104 A



Epitopea is a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies for hard-to-treat solid tumors. Epitopea's pipeline is built on Cryptigen™ TSAs, a new class of tumor-specific antigens identified by CryptoMap™, the company's proprietary immunopeptidomics and genomics platform that uncovers aberrantly expressed antigens arising from previously uncharacterized regions of the genome. The company's lead candidate, CryptiVax™-1001, is an off-the-shelf mRNA therapeutic vaccine expected to enter a first-in-human clinical trial (OVACT) for advanced, high-grade serous ovarian cancer (HGSOC) in Q2 2026. It is designed to drive targeted immune responses using a set of tumor-specific antigens chosen for broad patient coverage. Many patients with advanced cancers, including HGSOC, have limited durable treatment options and few effective therapies beyond biomarker-selected populations. Epitopea aims to address this unmet need with broadly applicable, tumor-selective immunotherapies. Epitopea operates from Cambridge, UK, and Montreal, Canada and is backed by a leading transatlantic life science investor syndicate that includes Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Le Fonds de Solidarité FTQ, Investissement Québec, adMare BioInnovations, Meltwind, IRiCoR, the Harrington Discovery Institute, and Novateur Ventures.

Eupraxia Pharmaceuticals

Tuesday April 21 | 11:00 AM

Room 104 C/D



Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Diffusphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the Diffusphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Exact Imaging

Tuesday April 21 | 11:00 AM
Room 104 A



Exact Imaging is the world's leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging's ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and target biopsies at those areas. For those cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates fast, simple MRI fusion-based targeting with the guidance of the micro-ultrasound system's 70-micron real-time resolution. The ExactVu micro-ultrasound system including the FusionVu application has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)), and Canada (Health Canada medical device license).

Feldan Therapeutics

Wednesday April 22 | 3:00 PM
Room 104 A



Feldan is a clinical-stage biotech company that specializes in the development of treatments based on the intracellular delivery of therapeutics. Feldan has developed the Feldan Shuttle, a proprietary peptide-based technology that enables safe, rapid, and efficient local delivery of antisense oligonucleotides to cells. This technology unlocks the potential for a new generation of therapeutics by giving access to intracellular targets that are otherwise beyond reach.

Flosonics Medical

Tuesday April 21 | 1:30 PM
Room 104 A



Flosonics Medical is a medical device company building the future of hemodynamic monitoring. Its flagship product, FloPatch, is an FDA-cleared, wireless, wearable Doppler ultrasound for real-time hemodynamic assessment at the bedside. Recently awarded a Vizient Innovative Technology contract, FloPatch is used in hospitals across the United States to guide fluid resuscitation in critically ill patients.

Fluid Biomed

Tuesday April 21 | 2:00 PM
Room 104 A



Fluid Biomed Inc. is a pioneering medical device company based in Calgary, Alberta, Canada focused on developing polymer-based stent technologies for the minimally invasive treatment of neurovascular disease and stroke. Supported by strong scientific evidence, promising human clinical trial data, and robust financial partnerships, the company is advancing toward breakthroughs in the care of brain aneurysm patients.

Grey Wolf Animal Health

Tuesday April 21 | 3:30 PM

Room 104 B



Grey Wolf Animal Health Corp. (TSXV:WOLF) is a diversified health company. Grey Wolf currently operates two business units: (1) Pharmacy and (2) Animal Health. The Pharmacy business unit compounds pharmaceuticals for the human and animal health markets in Canada. The Animal Health business unit focuses on sourcing, in-licensing, acquiring, and commercializing branded and generic pharmaceutical, nutraceutical, and consumable products for the animal health market. Over the last six years, the Company has grown organically, supported by the launch of over fifteen products, and three accretive acquisitions.

Groupe LSL Pharma

Tuesday April 21 | 4:00 PM

Room 104 B



LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing, and marketing of high-quality sterile ophthalmic pharmaceuticals, as well as solid, semi-solid, and liquid pharmaceutical, cosmetic, and natural health products. With its technical expertise, certified facilities, and experienced team, LSL Pharma provides high-quality solutions that meet the highest industry standards. LSL Pharma's wholly owned subsidiaries include Steri-Med Pharma Inc., Laboratoire LSL Inc., Virage Santé Inc., Dermolab Pharma Ltd., Laboratoire Du-Var Inc., and Juno OTC Inc.

HEALWELL AI

Wednesday April 22 | 2:00 PM
Room 104 C/D

HEALWELL AI

HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF".

Helus Pharma

Tuesday April 21 | 2:00 PM
Room 104 C/D



HELUS Pharma's mission is to provide treatments designed to foster durable improvements in mental health to help minds heal. We strategically innovate novel serotonergic agonists through rigorous patient-centered research and clinical excellence.

HLS Therapeutics

Tuesday April 21 | 3:00 PM
Room 104 B



Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products that address unmet needs in the treatment of psychiatric disorders and cardiovascular disease. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.

Innospera Pharma

Wednesday April 22 | 4:00 PM
Room 104 A



Innospera Pharma is a clinical-stage, private biotechnology company developing small-molecule lipid modulators for fibrotic diseases. Its lead candidate, ING-006, is a next-generation GPR84 modulator that has demonstrated robust anti-fibrotic activity in gold-standard preclinical models and is currently in Phase 1. Building on the clinical precedent established by earlier GPR84 modulators that have shown therapeutic potential in fibrotic and metabolic disorders, ING-006 combines a markedly improved pharmacological profile with an anticipated broad safety margin and favorable tolerability. The Company's pipeline includes additional modulators addressing other chronic conditions, including oncology.

Intellijoint Surgical

Tuesday April 21 | 11:30 AM
Room 104 A



Intellijoint Surgical® develops and commercializes surgical planning and navigation solutions for total hip and knee joint replacements. It is committed to improving patients' lives by providing every Orthopaedic Surgeon and their Care Team, access to easy-to-use technology. Intellijoint's technology is used by top orthopaedic institutions and surgeons globally.

Jade Biosciences

Tuesday April 21 | 10:30 AM
Room 104 C/D



Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade's lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. Jade's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an undisclosed antibody program, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Knight Therapeutics

Tuesday April 21 | 2:00 PM

Room 104 B



Knight Therapeutics Inc. is a pan-American (ex-US) specialty pharmaceutical company focused on acquiring, in licensing, out-licensing, marketing, and commercializing innovative prescription pharmaceuticals in Canada and Latin America. Headquartered in Montreal, Knight has operations in Canada and in 10 countries in Latin America and has over 700 employees globally. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD.

KYE Pharmaceuticals

Tuesday April 21 | 10:00 AM

Room 104 B



Kye Pharmaceuticals is a Canadian specialty pharmaceutical company based in Mississauga, Ontario, focused on licensing and commercializing innovative prescription therapies that are not otherwise available to patients across Canada. Kye's portfolio spans a range of therapeutic areas including neurology, psychiatry, pediatrics, rare diseases, hematology, cardiology and neuromuscular disorders. Kye partners with global pharmaceutical and biotechnology companies to license and launch medicines that matter, and deliver better outcomes to our partners, Canadian healthcare professionals, and most importantly, patients across Canada.

Medexus Pharma

Tuesday April 21 | 1:30 PM
Room 104 B



Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and rheumatology and allergy.

Medicenna Therapeutics

Tuesday April 21 | 3:00 PM
Room 104 C/D



Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's first-in-class targeted PD-1 x IL-2 bifunctional, MDNA113, is in development for solid tumors and was designed using the Company's proprietary BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and T-MASK™ (Targeted Metalloprotease Activated SuperKine) platforms. Medicenna's IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively.

Microbix Biosystems

Wednesday April 22 | 2:00 PM
Room 104 B



Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues of C\$18.5 million in its latest fiscal year (2025). It makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) and reference materials (QUANTDx™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs or QUANTDx are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products. Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario.

MolecuLight

Wednesday April 22 | 11:30 AM
Room 104 B



MolecuLight is a privately held medical imaging company with a global footprint, dedicated to manufacturing and commercializing the MolecuLight i:X® and DX® wound imaging devices. Both FDA-cleared Class II point-of-care systems provide real-time detection of elevated bacterial burden and accurate digital wound measurement. The MolecuLightDX® additionally offers thermal imaging for comprehensive wound assessment. The technologies' effectiveness and clinical utility are supported by more than 100 peer-reviewed publications.

NervGen Pharma

Wednesday April 22 | 11:00 AM
Room 104 A



NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company's mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen's lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide. NVG-291 was evaluated in the Phase 1b/2a CONNECT SCI Study in individuals with chronic SCI between 1 to 10 years post-injury and is the first pharmacologic candidate to demonstrate durable improvement in function, independence, and quality of life. Enrollment of individuals with subacute SCI in the Phase 1b/2a CONNECT SCI Study is ongoing, alongside preparation for a Phase 3 clinical trial in chronic SCI. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI. Through NVG-291 and the Company's next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need.

NeuPath Health

Wednesday April 22 | 2:30 PM
Room 104 C/D



NeuPath operates one of Canada's largest networks of community-based, multidisciplinary medical facilities focused on the assessment and treatment of chronic pain, musculoskeletal/back injuries, sports medicine and other pain medical services markets. NeuPath provides improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. Working within Canada's publicly funded healthcare system, NeuPath delivers insured medical services to help extend the appropriate care from hospitals into the community, which are complemented by select non-insured procedures to provide a comprehensive and coordinated treatment for patients. With operations across Ontario and Alberta, the Company addresses a significant and growing need, as an estimated 1 in 5 Canadians live with chronic pain.

Nicoya Lifesciences

Wednesday April 22 | 2:30 PM
Room 104 B



Nicoya is a global provider of lifescience analytical tools for biophysical and structural characterization, with over 3000 customers including most top 20 pharma companies. We are leading the charge in unblocking AI/ML discovery programs by providing high throughput, autonomous characterization tools with best-in-class performance. We are a profitable company with double digit growth and looking for the right capital partners to help us scale so reach out if you would like to learn more.

Northwyn Wellness Group

Wednesday April 22 | 3:00 PM
Room 104 C/D



Northwyn Wellness is a dedicated acquisition partner addressing the market's need for a specialized group that empowers founders in the medical aesthetics and wellness space. Through a unique partnership model, we maximize value while preserving the legacy founders have built. Our approach prioritizes long-term success, placing founders at the center of our strategy with an unwavering commitment to safety, quality, and innovation.

Nualtis

Tuesday April 21 | 3:30 PM
Room 104 A



At Nualtis, we're advancing oral film therapeutics designed for improved efficacy, faster onset, and better patient adherence. Our current pipeline addresses a wide range of therapeutic areas- each program built on proven science, human-centric design, and scalable manufacturing expertise.

Oligon Therapeutics

Wednesday April 22 | 4:00 PM
Room 104 C/D



Oligon Therapeutics (OligonTx) is a new biotechnology company pioneering RNA-based multi-targeting drugs as novel treatments for oncology, immunology, and other diseases. Oligon's proprietary SeekR™ technology platform represents the next generation of self-delivering therapeutic siRNA conjugates. The current pipeline includes two wholly owned therapeutic programs that reprogram specific immune cell subtypes. OligonTx also has a growing pipeline of partnered therapeutic programs with biopharma and academic collaborators, primarily targeting different types of cancer cells. OligonTx will also partner with additional pharma industry collaborators to further expand into additional new indications.

Perimeter Medical Imaging

Tuesday April 21 | 10:00 AM
Room 104 A



Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Claire, recently approved by the FDA, is our next-generation AI-enabled device. The Company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

PharmaCorp Rx

Tuesday April 21 | 9:30 AM
Room 104 B



PharmaCorp Rx Inc. (TSXV: PCRX) has acquired and continues to operate three Canadian-based pharmacies under the PharmaChoice banner. Through a Strategic Alliance Agreement, PharmaChoice Canada Inc. ("PCC") assigned PCRX the exclusive right-of-first refusal to acquire all PCC-bannered stores. This agreement provides PCRX with a robust acquisition pipeline, covering the ~1,100 independent pharmacies currently under the PCC banner, as well as future stores that join PCC's banner program, which is growing by ~40+ stores annually. Additionally, PCRX has the ability and intends to pursue acquisitions of non-PCC-bannered stores.

Pharmascience

Tuesday April 21 | 11:30 AM
Room 104 B



Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec. Headquartered in Montreal and employing 1,600 people, Pharmascience Inc. is a privately held, full-service pharmaceutical company with deep roots in Canada and a growing global reach, including distribution in over 50 countries. Ranked 52nd among Canada's top 100 R&D investors in 2023, with \$40-50 million in annual investments, Pharmascience Inc. is among Canada's largest drug manufacturers.

Profound Medical

Wednesday April 22 | 10:00 AM
Room 104 B



Profound is a commercial-stage medical device company and an innovator in interventional MRI procedures, enabling precise, incision-free therapies that improve clinical confidence, procedural control, and patient outcomes. By leveraging real-time MRI guidance, Profound's technologies are designed to replace uncertainty with clarity across treatment planning, delivery, and confirmation. The company's flagship platform, TULSA-PRO[®], enables MRI-guided, incision-free prostate therapy designed for precision and flexibility. Profound also commercializes Sonallev[®], an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.

ProMIS Neurosciences

Tuesday April 21 | 2:30 PM
Room 104 C/D



ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company's proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).

ProteinQure

Wednesday April 22 | 2:30 PM
Room 104 A

ProteinQure

ProteinQure is a clinical-stage biotech company focused on the design of novel exotic peptides with broad therapeutic applications. We recently announced the first clinical trial of a fully AI-designed peptide-drug conjugate in Canada and the United States.

Reverb Therapeutics

Wednesday April 22 | 9:30 AM

Room 104 A



Reverb's Amplify•R™ antibody platform intelligently controls and directs the body's own immune signals to treat cancer and auto-immune diseases. Our lead program in oncology augments the proven benefits of PD-1 inhibition by selectively amplifying immune signals to intensify the anti-tumor response, in a safe and controlled manner. Using proven biology and elegant rewiring of the immune system, we generate highly differentiated therapeutics, bringing new hope to patients for whom existing treatments have fallen short. Clinical trials are expected to start in early 2027.

Richards Group

Wednesday April 22 | 1:30 PM

Room 104 C/D



Richards Group Inc. is a Canadian publicly traded corporation listed on the Toronto Stock Exchange (symbol - RIC). Richards is known for a long history in packaging distribution, but has significantly transformed its mix of business over the last decade and is now primarily driven by its healthcare unit. The Richards Healthcare portfolio distributes medical devices and supplies across the aesthetics, pharmacy, and vision care verticals. The company recently made a significant step into the global medical device OEM space with a major acquisition during 2025.

Satellos Bioscience

Tuesday April 21 | 11:30 AM
Room 104 C/D



Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore muscle stem-cell signaling, a process that is disrupted in DMD. By addressing the loss of dystrophin-dependent cues, SAT-3247 may re-establish the signals that support effective muscle regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, initially for DMD. Satellos is also working to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities.

Sonic Incytes

Wednesday April 22 | 3:30 PM
Room 104 B



Sonic Incytes is committed to enhancing patient care through innovative diagnostic solutions. The company's flagship product, Velacur™, equips physicians with an advanced liver imaging tool to help manage the growing epidemic of fatty liver disease. Velacur offers real-time, AI guided quantification of the key markers for fatty liver disease: liver stiffness, attenuation and VDF. With real-time results, a low up-front cost and AI guidance, VELACUR makes liver imaging at the point of care affordable and accessible.

Specific Biologics

Wednesday April 22 | 2:00 PM
Room 104 A



Specific Biologics Inc. (“Specific”) is a preclinical biotechnology company developing its proprietary, industry-leading Dualase[®] genome editors to treat the untreatable with precise, efficient, and programmable in vivo genome editing. Specific’s initial therapeutic focus is the precise collapse of pathogenic DNA repeat expansions including in the C9ORF72 gene, the most frequent genetic cause of amyotrophic lateral sclerosis (ALS), where Dualase[®] has the potential of a durable, one-time treatment for patients who have no disease-modifying therapies today. The unique Dualase[®] two-site mechanism enables the seamless removal, repair, or insertion of both small and large DNA sequences, offering broad therapeutic potential, coupled with single AAV or all-RNA delivery. Dualase[®] achieves best-in-class accurate editing efficiency with undetectable off-target effects as demonstrated in preclinical cell and animal models at diverse targets and indications.

Spectral Medical

Wednesday April 22 | 10:30 AM
Room 104 B



At Spectral Medical, we are pioneering a transformative theranostic approach that will enable improved outcomes for patients with endotoxic septic shock (ESS). ESS is a life-threatening condition that arises when the body’s response to infection spirals into a storm of systemic inflammation. It’s characterized by a dangerous drop in blood pressure and a cascade of multiple organ failure caused by the presence of a bacterial toxin, known as endotoxin.

Synaptive Medical

Wednesday April 22 | 4:00 PM
Room 104 B

Synaptive

Synaptive Medical is a Toronto-based global medical technology company dedicated to solving complex challenges in surgery, imaging, and data integration to improve patient outcomes. Its integrated suite of solutions—spanning MRI, surgical planning, navigation, and robotic visualization—delivers intelligent, patient-centric technology that enhances clinical decision-making and efficiency across every stage of neurosurgical care.

Thiogenesis Therapeutics

Wednesday April 22 | 1:30 PM
Room 104 A

THiogenesis THERAPEUTICS

Thiogenesis Therapeutics is a clinical-stage biotechnology company developing next-generation sulfur-based therapeutics (thiols) designed to restore redox balance and reduce inflammation; key drivers of inherited and acquired mitochondrial disease.

Thornhill Medical

Wednesday April 22 | 11:00 AM
Room 104 B



Thornhill Medical is a global medical technology company built on a single, differentiated capability: the precise control and measurement of respiratory physiology. This shared technology core connects two distinct frontlines. Thornhill Medical's first line of effort is its dual-use, mission-proven critical care platform for austere and high-risk environments. Its commercialized solutions - including the flagship MOVES® SLC™, a micro-integrated portable life-support system with a built-in oxygen supply, and MADM™, its companion anesthesia module - are deployed in some of the world's toughest environments, from far-forward combat zones to disaster-relief missions, on land, at sea, and in the air, across the continuum of care. These technologies are deployed by military, emergency response, and disaster-relief organizations, including the U.S. Department of Defense and the Government of Canada, and in Ukraine's current conflict. Building on this proven technology foundation, Thornhill Medical is extending its capabilities into hospital settings through RespirAct®, its pre-commercial platform for advanced clinical brain diagnostics in Chronic Steno-Occlusive Disease, applying the same rigor, precision, and engineering excellence. Around the world, more than 80 research and clinical sites are using RespirAct® to advance their work. Grounded in science, validated through execution, and guided by disciplined growth, Thornhill Medical delivers with confidence.

Virica Biotech

Tuesday April 21 | 4:00 PM
Room 104 A



Cell and gene therapies offer curative solutions to diseases but face high costs, scalability issues, and low affordability impacting patient access. Cell & gene therapy and vaccine manufacturers face the challenge of rapid and scalable responses to meet global health demands. Current viral vector production strategies fail to address a fundamental challenge - innate cellular defenses. Virica is a cell enhancer company dedicated to improving manufacturing productivity and reducing costs, increasing access to cell and gene therapies by uniquely addressing the challenge of cellular defenses. Virica has developed a library of small molecule cell enhancers called Viral Sensitizers (VSE™), that temporarily reduce host cell defenses during production. This allows the virus to infect, transduce and replicate better. The outcome: higher yields, quality and scale-up success.

VitalHub

Wednesday April 22 | 11:30 AM
Room 104 C/D



VitalHub is a leading software company dedicated to empowering health and human services providers globally. VitalHub's comprehensive product suite includes electronic health records, operational intelligence, and workforce automation solutions that serve over 1,300 clients across the UK, Canada, and other geographies. The Company has a robust two-pronged growth strategy, targeting organic opportunities within its product suite and pursuing an aggressive M&A plan. VitalHub is headquartered in Toronto with over 700 employees globally, across key regions and the VitalHub Innovations Lab in Sri Lanka.

WELL Health Technologies

Wednesday April 22 | 9:30 AM
Room 104 C/D



WELL is building the infrastructure for a healthier Canada. Through its comprehensive healthcare and digital platforms, WELL operates the largest owned and operated outpatient healthcare ecosystem in Canada with more than 250 clinics, and its technology solutions enable more than 43,000 healthcare providers across Canada and the US. WELL's subsidiaries include WELLSTAR, a pure-play healthcare SaaS platform, HEALWELL AI, a global healthcare AI company, and CyberWELL, a healthcare cybersecurity division. WELL is publicly-traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'.

WELLSTAR

Wednesday April 22 | 10:30 AM
Room 104 C/D



WELLSTAR empowers healthcare providers with innovative technology and services to enhance patient care and operational efficiency. WELLSTAR's comprehensive range of products and solutions are designed to streamline care delivery, integrate fragmented healthcare systems, reduce provider burnout, and improve patient healthcare experiences and outcomes. WELLSTAR serves over 37,000 healthcare providers across Canada, representing over one-third of all healthcare providers in the country who utilize at least one of WELLSTAR's products, underscoring its extensive reach and trusted reputation in the industry. WELLSTAR stands out as a leader in Canada's healthcare technology landscape as the third-largest provider of EMR solutions in the country and holds the country's top position for e-referrals, digital health apps, and medical billing and RCM solutions.

Xenon Pharmaceuticals

Wednesday April 22 | 11:30 AM
Room 104 A



At Xenon, we are united by a common mission: to deliver innovative medicines that provide a brighter future for people living with neurological and psychiatric disorders. This purpose has driven our scientific curiosity and innovation in ion channel science, and it is enabling us to build a world-class, fully integrated company capable of turning scientific breakthroughs into life-changing medicines. The progress we've made since our founding fuels our optimism for the transformative potential of our pipeline to help patients who have been underserved for too long. From our science to our community partnerships, we are committed to making a meaningful impact and reshaping treatment paradigms.

Yellowbird Diagnostics

Tuesday April 21 | 10:30 AM
Room 104 A



Yellowbird Diagnostics is a clinical-stage company developing novel plug-and-play diagnostic agents to enhance disease detection in standard imaging procedures. Our lead asset NeuCaVis is a radiopharmaceutical that visualizes the metabolic driver of disease, inflammation, through PET imaging. NeuCaVis is in Phase I clinical trial this year, de-risked with remarkable first-in-human compassionate use data. This asset will redefine the PET imaging landscape. Yellowbird also has two other pre-clinically validated assets in our pipeline.

Zymeworks

Tuesday April 21 | 9:30 AM
Room 104 C/D



Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks' asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines.

ABOUT BLOOM BURTON & CO.



SINCE 2008, BLOOM BURTON HAS SERVED CANADIAN HEALTHCARE INVESTORS AND COMPANIES.

Our team has deep knowledge in medicine, science, finance, and healthcare innovation, development and commercialization. We are the ideal group to help companies plan their capital market strategies, investigate the relevance of new biological pathways, consider new therapeutic indications and clinical designs, as well as catalogue and conduct due diligence on new products or companies for acquisition. By speaking with key companies and investors every day, we know what they are seeking and how to help.

We identify the most impactful companies for our investor network and we provide tailor-made support solutions for management teams and boards of healthcare companies.



FAIRNESS OPINION



MARCH 2026

PLACEMENT & ENTITLEMENT OFFER

A \$600,000,000



**Global Joint Lead and North American Sole Lead
FEBRUARY 2026**

PUBLIC OFFERING

US \$57,200,000



Co-Manager

FEBRUARY 2026

PUBLIC OFFERING

US \$63,200,000



Co-Manager

FEBRUARY 2026

PUBLIC OFFERING

CDN \$12,000,000



Sole Agent

JANUARY 2026

PRIVATE PLACEMENT

CDN \$12,000,000



Sole and Exclusive Agent

DECEMBER 2025

BOUGHT DEAL

CDN \$23,000,000



Underwriter

NOVEMBER 2025

REGISTERED DIRECT OFFERING

US \$175,000,000



Agent

OCTOBER 2025

STRATEGIC ADVISORY



JULY 2025

STRATEGIC ADVISORY



MAY 2025

M&A ADVISORY



Advisor to Searchlight

APRIL 2024

FAIRNESS OPINION

US \$2,000,000,000



JUNE 2023

SERVICES

Our services **help identify, cultivate and create investment opportunities** in the healthcare sector on behalf of companies and investors.

From start-ups through commercial launches, we are active in all areas of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, digital health, life science tools, animal health, nutrition and wellness.

Our six business services work cohesively to accelerate monetization for both company and investor clients.



Capital Raising

Sourcing equity and debt capital for private and public companies

M&A Advisory

Enabling monetization through strategic transactions

Strategic Advisory

Scientific and business advisory services

Equity Research

Influential opinions and insights on companies

Sales & Trading

Generating returns for investors

Company Creation

Establishing and incubating new healthcare companies

SPONSORS





**TO OUR 2026 SPONSORS
FOR YOUR GENEROUS SUPPORT!**

BBHIC 2026

CONFERENCE INFORMATION

COMPANY PRESENTATIONS

Room 104 A
Room 104 B
Room 104 C/D

1X1 MEETINGS

Room 105

KEYNOTE ADDRESS AND PANEL DISCUSSIONS


Plenary Room
Room 106/107

QUESTIONS OR LOST AND FOUND

Registration Booth



NETWORK: BLOOM BURTON & CO.
PASSWORD: BBHIC2026





2026
BLOOM
BURTON
AWARD
GALA

September 24, 2026

The Ritz-Carlton

181 Wellington Street West, Toronto, Ontario

For Table Sponsorship Contact:

bbloom@bloomburton.com

 BLOOM BURTON & CO.

#BBHC2026



bloom burton & co

/accelerating returns in healthcare



NETWORK: BLOOM BURTON & CO.
PASSWORD: BBHC2026



Regulated by CIRO
Canadian Investment
Regulatory Organization

CIPF
Canadian Investor Protection Fund
MEMBER